MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once r ...

BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 6% higher at $102.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3% loss over the past four weeks.The sudden increase in the stock price can be attributed to the growing investor optimism about the company’s set of novel pipeline candidates being developed for treating various oncological indications and other serious diseases.This company ...

Core Insights - ITM Isotope Technologies Munich SE has elected Dr. Barbara Weber to its Supervisory Board, effective May 01, 2025, enhancing the board's expertise in advancing its radiopharmaceutical pipeline [1][2] - Dr. Weber brings over 25 years of experience in biotech and pharmaceutical industries, having held leadership roles at major companies and founded Tango Therapeutics [1][4] - The company is focused on developing its lead Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and expanding its pipeline of radiopharmaceuticals [1][3] Company Overview - ITM is a leading radiopharmaceutical biotech company dedicated to developing therapeutics and diagnostics for hard-to-treat tumors, aiming to improve patient outcomes through precision oncology [5] - The company has a broad pipeline that includes multiple Phase 3 studies, leveraging high-quality radioisotopes combined with various targeting molecules [5] Leadership and Expertise - Dr. Weber's background includes significant achievements in oncology drug development, including leading clinical studies that resulted in FDA approvals for several drugs [4] - As a physician-scientist, Dr. Weber emphasizes the potential of targeted radiopharmaceutical therapy to enhance precision oncology treatment [3]

智通财经APP讯，映恩生物-B(09606)于2025年4月7日至4月10日招股，公司拟全球发售1507.16万股股 份，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价94.6-103.2港元，每手 100股，预期股份将于2025年4月15日(星期二)开始在联交所买卖。 我们于2019年注册成立，是全球抗体偶联药物(ADC)领域的关键领跑者，致力于为癌症和自身免疫性疾 病等患者研发ADC创新药物。我们拥有自主研发的两款核心产品，即DB-1303/BNT323(一款靶向癌症 (包括子宫内膜癌(EC)及乳腺癌(BC))的HER2 ADC候选药物)及DB-1311/BNT324(一款靶向癌症(包括小细 胞肺癌(SCLC)、去势抵抗性前列腺癌(CRPC)、食管鳞状细胞癌(ESCC)及头颈部鳞状细胞癌(HNSCC))的 B7-H3 ADC候选药物)。 除核心产品外，我们还自主研发了：五款其他临床阶段ADC(即DB-1310、DB-1305/BNT325、DB- 1312/BGC9074、DB-1419及DB-2304)，在广泛适应症中具有潜力，根据Frost & Sullivan，就总体或主 ...

Shares of Moderna and Novavax dropped more than 11% and 6%, respectively, in early trading. Meanwhile, the SPDR S&P Biotech ETF slid nearly 5%. Shares of Pfizer , which has broader businesses to insulate it from damage to its vaccine portfolio, lost about 2%. The departure of Peter Marks, the Food and Drug Administration's top vaccine regulator, has raised fresh fears about whether the Trump administration will quickly approve and promote critical shots. In his position, Marks oversaw the introduction of Co ...

Group 1 - BioNTech SE is a significant player in mRNA-based cancer therapies and vaccines for virus immunization [1] - The company plans to expand its oncology pipeline by adding candidates such as FixVac, iNeST, and BNT327 by 2025 [1]

BioNTech (BNTX) Q4 2024 Earnings Call March 10, 2025 08:17 PM ET Company Participants Michael Horowicz - Director - IRUgur Sahin - Co-Founder, CEO & Chair of the Management BoardÖzlem Türeci - Co-Founder, Chief Medical Officer & Member of Management BoardJens Holstein - CFORyan Richardson - Chief Strategy OfficerAkash Tewari - Managing DirectorTazeen Ahmad - MD - US Equity ResearchHarry Gillis - Vice President - Pharmaceuticals Equity ResearchCory Kasimov - Senior Managing Director Conference Call Participa ...

BioNTech SE (NASDAQ:BNTX) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Fl ...

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.Biopharmaceutical company BioNTech SE (BNTX -1.85%) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1.19 billion euros, ahead of estimates for 1.14 billion but down nearly 43% from the prior year's quarter. Earnings per share (EPS) stood at 1.08 euros against the expected 0.42 euros, a significant o ...